- Home
- CTOS vs TRVI Comparison
CTOS vs TRVI Comparison
Compare CTOS & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTOS | TRVI |
|---|---|---|
| Founded | 1988 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CTOS | TRVI |
|---|---|---|
| Price | $6.52 | $11.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $7.50 | ★ $20.38 |
| AVG Volume (30 Days) | 793.9K | ★ 1.5M |
| Earning Date | 03-03-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,936,513,000.00 | N/A |
| Revenue This Year | $13.19 | N/A |
| Revenue Next Year | $5.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.39 | N/A |
| 52 Week Low | $3.18 | $3.77 |
| 52 Week High | $6.80 | $14.39 |
Technical Indicators
Market Signals| Indicator | CTOS | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 58.15 | 51.17 |
| Support Level | $6.17 | $10.25 |
| Resistance Level | $6.80 | $11.65 |
| Average True Range (ATR) | 0.22 | 0.70 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 59.91 | 75.79 |
Price Performance
Historical ComparisonAbout CTOS Custom Truck One Source Inc.
Custom Truck One Source Inc is a one-stop-shop provider of specialty equipment in the electric utility transmission and distribution, forestry, telecom, waste management, rail, and infrastructure end-markets in North America. The company's segment includes Equipment Rental Solutions (ERS), Truck and Equipment Sales (TES), and Aftermarket Parts and Services (APS). It generates maximum revenue from the TES segment. Geographically, it derives a majority revenue from the United States.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.